T cell senescence and cardiovascular diseases

Clinical and Experimental Medicine

Volumn 16, Issue 3, 2016, Pages 257-263

  Yu, Hee Tae ^a,b   Park, Sungha ^b   Shin, Eui Cheol ^a   Lee, Won Woo ^c,d  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Cardiovascular disease (CVD); Cytomegalovirus (CMV); Immunosenescence; Inflammaging

Indexed keywords

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL AGING; CELLULAR IMMUNITY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; ESSENTIAL HYPERTENSION; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSENESCENCE; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; AGE; AGING; CARDIOVASCULAR DISEASES; IMMUNOLOGY; PATHOLOGY; SECRETION (PROCESS);

CYTOKINE;

AGE FACTORS; AGING; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; T-LYMPHOCYTES;

EID: 84937131109     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0376-z     Document Type: Review

References (84)

1. Grubeck-Loebenstein B, Berger P, Saurwein-Teissl M, Zisterer K, Wick G. No immunity for the elderly. Nat Med. 1998;4(8):870.
2. Nikolich-Zugich J. T cell aging: naive but not young. J Exp Med. 2005;201:837–40.
3. Nikolich-Zugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol. 2008;8(7):512–22. doi:10.1038/nri2318.
4. Miller RA. The aging immune system: primer and prospectus. Science. 1996;273(5271):70–4.
5. Weng NP. Aging of the immune system: How much can the adaptive immune system adapt? Immunity. 2006;24(5):495–9. doi:10.1016/j.immuni.2006.05.001.
6. Brody JA, Brock DB. Handbook of the biology of aging. London: Nature Publishing Group; 1985. p. 3–42.
7. Robinson KA. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–35.
8. Gardner ID. The effect of aging on susceptibility to infection. Rev Infect Dis. 1980;2:801–10.
9. Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence during aging. Curr Opin Immunol. 2005;17(5):480–5.
10. Yoshikawa TT. Perspective: aging and infectious diseases: past, present, and future. J Infect Dis. 1997;176(4):1053–7.
11. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75(24):12182–7. doi:10.1128/JVI.75.24.12182-12187.2001.
12. Weksler ME, Pawelec G, Franceschi C. Immune therapy for age-related diseases. Trends Immunol. 2009;30(7):344–50. doi:10.1016/j.it.2009.03.011.
13. Woodland DL, Blackman MA. Immunity and age: Living in the past? Trends Immunol. 2006;27(7):303–7. doi:10.1016/j.it.2006.05.002.
14. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179–86.
15. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357(14):1373–81. doi:10.1056/NEJMoa070844.
16. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005;352(22):2266–7. doi:10.1056/NEJMp058091.
17. Goronzy JJ, Li G, Yang Z, Weyand CM. The janus head of T cell aging—autoimmunity and immunodeficiency. Front Immunol. 2013;4:131. doi:10.3389/fimmu.2013.00131.
18. Goronzy JJ, Weyand CM. Immune aging and autoimmunity. Cell Mol Life Sci. 2012;69(10):1615–23. doi:10.1007/s00018-012-0970-0.
19. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428–36. doi:10.1038/ni.2588.
20. Cavanagh MM, Weyand CM, Goronzy JJ. Chronic inflammation and aging: DNA damage tips the balance. Curr Opin Immunol. 2012;24(4):488–93. doi:10.1016/j.coi.2012.04.003.
21. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune system. Curr Opin Immunol. 2010;22(4):507–13. doi:10.1016/j.coi.2010.05.003.
22. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54.
23. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American heart association. Circulation. 2012;125(1):e2–220. doi:10.1161/CIR.0b013e31823ac046.
24. Fulop T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013;4:271. doi:10.3389/fimmu.2013.00271.
25. Dowling MR, Hodgkin PD. Why does the thymus involute? A selection-based hypothesis. Trends Immunol. 2009;30(7):295–300. doi:10.1016/j.it.2009.04.006.
26. Steinmann GG. Changes in the human thymus during aging. Curr Top Pathol. 1986;75:43–88.
27. Steinmann GG, Klaus B, Muller-Hermelink HK. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand J Immunol. 1985;22(5):563–75.
28. Lamar LL, Weyand CM, Goronzy JJ. Age, T-cell homeostasis, and T-cell diversity in humans. In: Fülöp T, Franceschi C, Hirokawa K, Pawelec G, SpringerLink (Online service), editors. Handbook on immunosenescence basic understanding and clinical applications, vol I. Dordrecht: Springer; 2009. p. 167–92.
29. Naylor K. The influence of age on T cell generation and TCR diversity. J Immunol. 2005;174:7446–52.
30. den Braber I, Mugwagwa T, Vrisekoop N, Westera L, Mögling R, de Boer AB, et al. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity. 2012;36(2):288–97. doi:10.1016/j.immuni.2012.02.006.
31. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity. 2008;29(6):848–62. doi:10.1016/j.immuni.2008.11.002.
32. Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr Opin Immunol. 2005;17(5):468–75. doi:10.1016/j.coi.2005.07.020.
33. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396(6712):690–5.
34. Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp Gerontol. 2007;42(5):400–6. doi:10.1016/j.exger.2006.11.016.
35. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee JY, et al. Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci USA. 2014;111(36):13139–44. doi:10.1073/pnas.1409155111.
36. Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ, et al. T cell subset-specific susceptibility to aging. Clin Immunol. 2008;127(1):107–18. doi:10.1016/j.clim.2007.12.002.
37. Henson SM, Riddell NE, Akbar AN. Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol. 2012;24(4):476–81. doi:10.1016/j.coi.2012.04.001.
38. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379–85.
39. Cavanagh MM, Qi Q, Weyand CM, Goronzy JJ. Finding balance: T cell regulatory receptor expression during aging. Aging Dis. 2011;2(5):398–413.
40. Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstein B, Wikby A. Is immunosenescence infectious? Trends Immunol. 2004;25(8):406–10. doi:10.1016/j.it.2004.05.006.
41. Pawelec G. Immunosenenescence: role of cytomegalovirus. Exp Gerontol. 2014;54C:1–5. doi:10.1016/j.exger.2013.11.010.
42. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169(4):1984–92.
43. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci. 2007;1114:23–35. doi:10.1196/annals.1396.043.
44. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673–85. doi:10.1084/jem.20050882.
45. Ouyang Q, Wagner WM, Zheng W, Wikby A, Remarque EJ, Pawelec G. Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly. Exp Gerontol. 2004;39(4):607–13. doi:10.1016/j.exger.2003.11.016.
46. Karrer U, Sierro S, Wagner M, Oxenius A, Hengel H, Koszinowski UH, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol. 2003;170(4):2022–9.
47. O’Hara GA, Welten SP, Klenerman P, Arens R. Memory T cell inflation: understanding cause and effect. Trends Immunol. 2012;33(2):84–90. doi:10.1016/j.it.2011.11.005.
48. Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol. 2009;21(4):440–5. doi:10.1016/j.coi.2009.05.012.
49. Globerson A, Effros RB. Ageing of lymphocytes and lymphocytes in the aged. Immunol Today. 2000;21(10):515–21.
50. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134(1):17–32. doi:10.1111/j.1365-2567.2011.03470.x.
51. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005;60(5):556–65.
52. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.
53. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, et al. Effector memory T cells are associated with atherosclerosis in humans and animal models. J Am Heart Assoc. 2012;1(1):27–41.
54. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10):2449–60.
55. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122(24):2529–37.
56. Fish KN, Soderberg-Naucler C, Mills LK, Stenglein S, Nelson JA. Human cytomegalovirus persistently infects aortic endothelial cells. J Virol. 1998;72(7):5661–8.
57. Bentz GL, Yurochko AD. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and β1 and β3 integrins. Proc Natl Acad Sci USA. 2008;105(14):5531–6.
58. Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, et al. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 2009;5(5):e1000427.
59. Núñez J, Chilet M, Sanchis J, Bodí V, Núñez E, Miñana G, et al. Prevalence and prognostic implications of active cytomegalovirus infection in patients with acute heart failure. Clin Sci. 2010;119(10):443–52.
60. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6(2):e16103.
61. Wall NA, Chue CD, Edwards NC, Pankhurst T, Harper L, Steeds RP, et al. Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease. PLoS One. 2013;8(2):e55686.
62. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.
63. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–12.
64. Spyridopoulos I, Hoffmann J, Aicher A, Brummendorf TH, Doerr HW, Zeiher AM, et al. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation. 2009;120(14):1364–72. doi:10.1161/CIRCULATIONAHA.109.854299.
65. Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G, et al. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation. 2001;103(24):2915–21.
66. Grahame-Clarke C, Chan NN, Andrew D, Ridgway GL, Betteridge DJ, Emery V, et al. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation. 2003;108(6):678–83. doi:10.1161/01.CIR.0000084505.54603.C7.
67. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet. 2001;358(9280):472–3.
68. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23(5):842–6.
69. Olson NC, Doyle MF, Jenny NS, Huber SA, Psaty BM, Kronmal RA, et al. Decreased naive and increased memory CD4(+) T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis. PLoS One. 2013;8(8):e71498. doi:10.1371/journal.pone.0071498.
70. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203(4):452–63.
71. Liuzzo G, Kopecky SL, Frye RL, O’Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 1999;100(21):2135–9.
72. Bergström I, Backteman K, Lundberg A, Ernerudh J, Jonasson L. Persistent accumulation of interferon-γ-producing CD8+ CD56+ T cells in blood from patients with coronary artery disease. Atherosclerosis. 2012;224(2):515–20.
73. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101(25):2883–8.
74. Leon MA, Zuckerman S. Gamma interferon: a central mediator in atherosclerosis. Inflamm Res. 2005;54(10):395–411.
75. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther. 2007;5(2):265–82.
76. Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M, Digianuario G, et al. Unusual CD4+ CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol. 2007;50(15):1450–8.
77. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347(1):5–12.
78. Yu HT, Youn JC, Lee J, Park S, Chi HS, Lee J, et al. Characterization of CD8CD57 T cells in patients with acute myocardial infarction. Cell Mol Immunol. 2014. doi:10.1038/cmi.2014.74.
79. Brugaletta S, Biasucci L, Pinnelli M, Biondi-Zoccai G, Di Giannuario G, Trotta G, et al. Novel anti-inflammatory effect of statins: reduction of CD4+ CD28null T lymphocyte frequency in patients with unstable angina. Heart. 2006;92(2):249–50.
80. Link A, Selejan S, Hewera L, Walter F, Nickenig G, Böhm M. Rosuvastatin induces apoptosis in CD4+ CD28null T cells in patients with acute coronary syndromes. Clin Res Cardiol. 2011;100(2):147–58.
81. Youn J-C, Yu HT, Lim BJ, Koh MJ, Lee J, Chang D-Y, et al. Immunosenescent CD8+ T cells and CXC chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013;62(1):126–33.
82. Madhur MS, Harrison DG. Senescent T cells and hypertension new ideas about old cells. Hypertension. 2013;62(1):13–5.
83. Trott DW, Thabet SR, Kirabo A, Saleh MA, Itani H, Norlander AE, et al. Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertension. 2014;64(5):1108–15. doi:10.1161/HYPERTENSIONAHA.114.04147.
84. Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124(10):4642–56. doi:10.1172/JCI74084.